Quelling of Excitotoxicity in Acute Stroke With Ketamine
The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.
- Status
- planned
- Phase
- Phase 2, Phase 3
- Institution
- Lower Merion Neurology Research Foundation
- Start date
- 2024-07-01
- End date
- 2027-12-31
- Registry ID
- NCT03223220
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.